Shanghai Henlius Biotech

This study is testing HLX13, a biosimilar (highly similar copy) of the cancer drug ipilimumab, in people with advanced liver cancer that cannot be removed by surgery. The main goal is to see if HLX13 behaves similarly in the body to the original drug and is safe. Researchers will…

This study is testing if a new drug called HLX17 works similarly to the established cancer drug Keytruda. It aims to prevent cancer from returning in people who have had surgery for certain lung, skin, or kidney cancers. Researchers will compare how the two drugs are processed by…

This study is testing a new two-drug combination (HLX43 plus serplulimab) given to patients before they have surgery for non-small cell lung cancer. The goal is to see if this treatment can shrink or eliminate the tumor to make surgery more effective. The study will enroll 60 adu…

This is a first-in-human study to test the safety and find the right dose of a new experimental drug called HLX42. It is for adults with advanced solid tumors or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to see how much of t…

This study is testing an experimental drug called HLX43 for women with advanced cervical or ovarian cancer that has returned or spread after standard first treatments didn't work or caused severe side effects. The Phase 2 trial will enroll about 130 participants to find the right…

This is a first-in-human study to check the safety and side effects of a new experimental drug called HLX37 in people with advanced or spreading solid tumors, including a type of lung cancer (NSCLC). The drug is designed to block two pathways that help tumors grow. The main goal …

This study is testing an experimental drug called HLX43 for people with advanced nasopharyngeal cancer (a type of throat cancer) that has returned or spread and hasn't responded to at least two previous treatments. The trial will enroll 70 participants to receive one of three dif…

This study is testing a new drug, HLX79, given alongside an existing drug called rituximab, to see if it is safe and can help control active kidney disease caused by membranous nephropathy or lupus. It will involve about 24 adults who have not responded well to standard care. The…

This study is testing an experimental drug called HLX43 for people with advanced stomach or gastroesophageal junction cancer that has continued to grow despite standard treatments. The trial aims to find a safe and effective dose while measuring how well the drug shrinks tumors a…

This study is testing a new combination of two immunotherapy drugs, HLX43 and serplulimab, for people with advanced solid tumors or a specific type of lung cancer. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. It will enroll a…

This study is testing an experimental drug called HLX43 for people with advanced esophageal cancer that has returned or spread after standard treatment failed. The trial aims to find a safe and effective dose and see if the drug can help control the cancer. About 72 participants …

This is the first human study of an experimental cancer drug called HLX43. Researchers are testing its safety and how it moves through the body in 340 adults with advanced solid tumors that have spread or don't respond to standard treatments. The study will find the safest dose a…

This study is testing an experimental drug called HLX43 in people with advanced colorectal cancer that has continued to grow despite standard treatments. About 60 participants will receive the drug at different doses to find the best balance of effectiveness and safety. The main …

This study is testing a new two-drug combination (HLX22 and HLX87) as the first treatment for people with advanced or spreading HER2-positive breast cancer. It aims to see if this combination can better control the cancer and help patients live longer without their disease gettin…

This study is testing whether adding a new immunotherapy drug called HLX10 to standard chemotherapy helps control advanced small cell lung cancer. It is for Japanese patients who have not yet received any treatment for their extensive-stage cancer. The main goal is to see how wel…

This study is testing an experimental drug called HLX43 for people with advanced head and neck cancer that has returned or spread. The main goals are to find a safe and effective dose, see if it shrinks tumors, and monitor side effects. About 167 participants will receive the dru…

This large Phase 3 study is testing whether adding a new antibody drug called HLX22 to standard treatment helps people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer getting worse. About 550 adults with previously untreated, advanc…